Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.
TBPH SEC Filing Email Alerts Service
Company Name: |
Theravance Biopharma, Inc. |
Website: |
www.theravance.com |
Sector: |
Biotechnology |
Number of ETFs Holding TBPH: |
28 |
Total Market Value Held by ETFs: |
$48.38M |
Total Market Capitalization: |
$425.00M |
% of Market Cap. Held by ETFs: |
11.38% |
|
|
March 29, 2024 4:05 AM Eastern
Buy (3.00 out of 4)
25th percentile
|
|